55 results
8-K
EX-10.1
PCSA
Processa Pharmaceuticals Inc
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
Control of the U.S. Treasury Department (“OFAC”).
(mm) U.S. Real Property Holding Corporation. The Company is not and has never been a U.S. real
8-K
PCSA
Processa Pharmaceuticals Inc
21 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:29pm
Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the bid
8-K
EX-10.1
60p10guf384u3xv57
24 Mar 22
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-1.1
krtq0tz3g 8su
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
ktglsd oo
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
8-K
EX-10.1
qvimg gezav
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-1.1
qhx7ytlapwglac8w wz
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
86kj44x9fwu4qvr4c6dk
5 Oct 20
Prospectus supplement with pricing info
4:16pm